New agents in the MF therapeutic landscape

During the MPN Hub Steering Committee meeting, we invited Steffen Koschmieder, Uniklinikum RWTH Aachen, Aachen, DE, to give a presentation and chair a discussion on new agents in the myelofibrosis (MF) therapeutic landscape. MPN Hub Steering Committee members Jean-Jacques Kiladjian, Haifa Kathrin Al-Ali, Tiziano Barbui, and Laura Michaelis joined the discussion.

In this video, Steffen Koschmieder discusses recent clinical trials in MF, including MOMENTUM, BOREAS, IMpactMF, MANIFEST-2, TRANSFORM-1, LIMBER-313, and INDEPENDENCE. Koschmieder details the study designs and endpoints, as well as results data available to date. The committee members discuss data from each trial and the potential implications for the management of MF.